Compare Prudential PLC (PUK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Regeneron Pharmaceuticals Inc — how do they compare? Prudential PLC trades at $29.47 (market cap $35.71B), while Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Prudential PLC pays the higher dividend (1.84%). Which is the better fit depends on your goals.
| PUK | REGN | |
|---|---|---|
Market Cap | $35.71B | $70.79B |
Sector | Financials | Health |
52-Week High | $33.61 | $812.27 |
52-Week Low | $24.80 | $545.46 |
Enterprise Value | $37.15B | $64.74B |
Dividend Yield | 1.84% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $28.88, up 2.09% today, showing strong fundamental momentum with revenue growth from $16.21B in 2024 to $27.4B projected for 2025 and consistent earnings beats. The stock appears undervalued with a P/E of 9.21 and P/S of 1.34, while technical indicators show a bearish trend despite neutral oscillators. Recent news highlights JP Morgan's positive catalyst watch ahead of August earnings and strategic moves in Asian markets.
The outlook remains positive given strong profitability (21.15% ROE) and analyst support (50% buy ratings), but risks include regulatory challenges in Japan and China exposure. Current valuation metrics suggest potential upside if earnings momentum continues, though technical resistance near $29 may limit near-term gains.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
